Nog even een verduidelijk waarom GTCB een goed fundament heeft:
Cox:
"It's always difficult to judge investors' perspectives, and different investors have, obviously, different opinions and different strategies for why they buy a stock. You know, our strategy has always been to try and be very transparent with investors about what we're trying to do and why we're doing it, to set out a timetable for doing those things, and try and stick to that timetable.
We're very consistent about hitting our milestones. And I'm very happy that we've continued to do that. So I think that all we can do is keep doing our bit from a management point of view. I think that it will become very obvious to people as we move forward over the coming months that we have good news flow, we're doing the things we've said we would do, and we're beginning to develop a group of products, not only with ATryn(R), but also with our other products, which have tremendous value, and which people can clearly identify what the value of those opportunities are.
The plasma products industry is a - - probably somewhere around - -about a $10 billion business today, but it has been significantly limited by availability of supplies, inadequate clinical development, many of these products were grandfathered from many years ago, and concerns about safety of the blood supply. Those products is not only captured a significant part of the existing plasma products marketplace, but they've actually developed a marketplace which didn't exist previously. And we think that's a great model for us and a great opportunity for us as we move forward. And recognizing the fact that many of these plasma proteins are extremely difficult to express in other manufacturing systems, and so we have a - - I think we have a great opportunity to leverage this technology.